Earnings & Valuation
This table compares Defiance Daily Target 2X Long LMND ETF and Interpace Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Defiance Daily Target 2X Long LMND ETF | $437.66 million | 0.01 | $15.17 million | $0.51 | 38.24 |
| Interpace Biosciences | $38.73 million | 0.25 | $24.58 million | ($0.02) | -110.00 |
Interpace Biosciences has lower revenue, but higher earnings than Defiance Daily Target 2X Long LMND ETF. Interpace Biosciences is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Profitability
This table compares Defiance Daily Target 2X Long LMND ETF and Interpace Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Defiance Daily Target 2X Long LMND ETF | 5.39% | 4.66% | 2.91% |
| Interpace Biosciences | 63.46% | 493.02% | 137.46% |
Insider & Institutional Ownership
87.8% of Defiance Daily Target 2X Long LMND ETF shares are held by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are held by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are held by insiders. Comparatively, 5.5% of Interpace Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Defiance Daily Target 2X Long LMND ETF beats Interpace Biosciences on 6 of the 11 factors compared between the two stocks.
About Defiance Daily Target 2X Long LMND ETF
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
About Interpace Biosciences
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Defiance Daily Target 2X Long LMND ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defiance Daily Target 2X Long LMND ETF and related companies with MarketBeat.com's FREE daily email newsletter.
